BI 655064

Drug Profile

BI 655064

Alternative Names: BI-655064

Latest Information Update: 20 Feb 2017

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD40 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lupus nephritis
  • Phase I Immune thrombocytopenic purpura; Rheumatoid arthritis

Most Recent Events

  • 11 Nov 2016 Efficacy, adverse events, pharmacodynamics and immunogenecity data from a phase I trial in Rheumatoid arthritis presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR-ARHP-2016)
  • 28 Sep 2016 Boehringer Ingelheim terminates a phase I trial for Immune thrombocytopenic purpura in the US (NCT02009761)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in Germany (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top